Context Therapeutics Inc (CNTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Context Therapeutics Inc (CNTX) has a cash flow conversion efficiency ratio of -0.090x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.58 Million) by net assets ($73.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Context Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Context Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Context Therapeutics Inc (CNTX) financial obligations for a breakdown of total debt and financial obligations.
Context Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Context Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
EMS Limited
NSE:EMSLIMITED
|
-0.031x |
|
Xiongan Kerong Environment Technology Co Ltd
SHE:300152
|
-0.004x |
|
BEXIMCO PHARMA.GDR REGS 1
F:R2WA
|
N/A |
|
AIRA Capital Public Company Limited
BK:AIRA
|
-0.022x |
|
Huons Co. Ltd
KQ:243070
|
0.028x |
|
Kejuruteraan Asastera Bhd
KLSE:0193
|
-0.273x |
|
Senseonics Holdings, Inc. Common Stock
NYSE MKT:SENS
|
-0.202x |
|
Atrium Therapeutics, Inc. Common Stock
NASDAQ:RNA
|
-0.093x |
Annual Cash Flow Conversion Efficiency for Context Therapeutics Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Context Therapeutics Inc from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Context Therapeutics Inc (CNTX) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $95.27 Million | $-14.56 Million | -0.153x | +91.38% |
| 2023-12-31 | $11.87 Million | $-21.05 Million | -1.773x | -354.84% |
| 2022-12-31 | $34.76 Million | $-13.55 Million | -0.390x | -113.84% |
| 2021-12-31 | $48.27 Million | $-8.80 Million | -0.182x | -398.13% |
| 2020-12-31 | $-16.92 Million | $-1.03 Million | 0.061x | -48.34% |
| 2019-12-31 | $-23.96 Million | $-2.84 Million | 0.118x | +131.22% |
| 2017-12-31 | $58.95 Million | $-22.35 Million | -0.379x | +83.73% |
| 2016-12-31 | $13.12 Million | $-30.57 Million | -2.331x | -- |
About Context Therapeutics Inc
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the developm… Read more